Institution Directory

Clinical trials at University of Alabama at Birmingham

Sites in Birmingham, AL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1238

Shown on this page

Current sort

Live official records

Conditions: Myopia
Interventions: MiSight 1 Day, Proclear 1 day; Device
Lead sponsor: CooperVision, Inc.; Industry
Eligibility: 8 Years to 12 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 30
States / cities: Birmingham, Alabama • Fullerton, California • La Mesa, California + 26 more

Conditions: Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis, ILD, Normal Controls
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Preeclampsia
Interventions: Sample collection; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2031
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Colorectal Cancer
Interventions: Fruquintinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Interventions: JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 83
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more

Conditions: Cystic Fibrosis Lung
Interventions: 4D-710; Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more

Conditions: Moderate Aortic Valve Stenosis
Interventions: Ataciguat, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 61 more

Conditions: Lung Cancer
Interventions: Low-dose CT scan; Device
Lead sponsor: Guardant Health, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 12,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 125
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Anaheim, California + 105 more

Conditions: Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal, Intensive Care Units, Neonatal
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 0 Years to 1 Year
Enrollment: 5,000 participants
Timeline: 2019 – 2030
U.S. locations: 43
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 30 more

Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
Interventions: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs); Drug
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: Not listed
Enrollment: 99,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2041
U.S. locations: 142
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more

Conditions: Oncology, Myeloid Leukemia, Acute, Cancer
Interventions: UR-GOAL; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 60 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Birmingham, Alabama • Rochester, New York • Chapel Hill, North Carolina + 1 more

Conditions: Pelvic Organ Prolapse
Interventions: Platelet rich plasma (PRP) Injection, Placebo; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

About this University of Alabama at Birmingham institution page

What this page lists: ClinicalTrials.gov records that list University of Alabama at Birmingham in Birmingham, AL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Alabama at Birmingham

Filter and sort this campus

Live official records

MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms

High Resolution Micro OCT Imaging

Exosome Cargo From Preeclampsia Patients

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

4D-710 in Adult Patients With Cystic Fibrosis

Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

Screening for High Frequency Malignant Disease

Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Platelet Rich Plasma as an Adjunct Therapy at the Time of Transvaginal Native Tissue Prolapse Surgery

About this University of Alabama at Birmingham institution page